Eisai and Biogen launch Leqembi Iqlik autoinjector for at-home Alzheimer's treatment

Overview

Updated Aug 25

Since 2023 the Alzheimer's drug Leqembi came with a catch: patients needed intravenous infusions at a clinic every two weeks for 18 months. On August 24, Eisai and Biogen removed that hurdle, making a subcutaneous autoinjector version, LEQEMBI IQLIK, available from the very first dose.

The drug is the same — lecanemab, an antibody that clears amyloid plaques. What changed is delivery: two 15-second injections at home once a week replace a trip to the infusion center. That matters because roughly 80% of Leqembi patients need a caregiver to accompany them to those visits.

Why it matters

The biggest practical barrier to Alzheimer's treatment — clinic visits for infusions — just fell, opening the way for many more patients to start therapy.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

500 mg

Weekly induction dose

Two 250 mg subcutaneous injections given once a week at the start of therapy.

94%

Patients and care partners rating the autoinjector easy to use

From an Eisai acceptability study of the device.

80%

Patients needing a caregiver at infusion visits

Share of people on anti-amyloid therapy who had a caregiver accompany them to the clinic, per clinician reporting.

18 months

Time before the lower maintenance dose applies

After 18 months of treatment, patients can move to a 360 mg weekly maintenance dose.

15 sec

Time per injection

Each 250 mg injection delivers in about 15 seconds.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Haruo Naito

Chief Executive Officer, Eisai

Overseeing Leqembi development and the US launch of IQLIK

Christopher Viehbacher

Chief Executive Officer, Biogen

Co-marketing Leqembi and IQLIK in the US

Gunilla Osswald

Chief Executive Officer, BioArctic

Original developer of the antibody; receives royalties on IQLIK sales

Organizations Involved

Eisai Co., Ltd.

Pharmaceutical company

Lead developer and worldwide marketer of Leqembi

Japanese drugmaker that developed and markets lecanemab, with Biogen co-marketing in the US.

Biogen

Biotechnology company

Co-marketing Leqembi and IQLIK in the US

US biotech co-marketing Leqembi and IQLIK with Eisai, sharing costs and profits.

BioArctic AB

Biotechnology company

Original inventor; earns royalties on Leqembi and IQLIK

Swedish firm that developed the antibody behind Leqembi and licensed it to Eisai.

Timeline

January 2023 August 2026

5 events Latest: August 24th, 2026 · 3 weeks ago

Tap a bar to jump to that date

August 2026
IQLIK autoinjector launches in the US
Latest Launch

Eisai and Biogen make the at-home subcutaneous version available from the first dose for early Alzheimer's patients.
August 24th, 2026
July 2026
FDA approves IQLIK as an initiation dose
Regulatory

The agency clears once-weekly subcutaneous lecanemab from the start of treatment, backed by exposure-equivalence data.
July 13th, 2026
2025
FDA approves IQLIK for maintenance dosing
Regulatory

The autoinjector clears the agency for use after 18 months of IV or subcutaneous treatment.
2025
July 2023
FDA confirms Leqembi's benefit
Regulatory

The agency converts accelerated approval to traditional approval after a confirmatory trial showed slower cognitive decline.
July 6th, 2023
January 2023
FDA approves Leqembi IV under accelerated approval
Regulatory

The first anti-amyloid drug to win approval since Aduhelm, cleared for patients with early Alzheimer's.
January 6th, 2023

Scenarios

At-home Leqembi widens access as patient numbers climb

Likely Resolves by Aug 24, 2027

Discussed by: Industry analysts and Eisai executives, covered by Being Patient and pharma trade press

With infusion trips no longer required, patients who could not arrange clinic visits can now start therapy, including older adults without a caregiver. Eisai expects IQLIK to shorten the time from diagnosis to first dose. If adoption accelerates, Eisai's fiscal 2027 reporting should show a clear uptick in patients on lecanemab.

Missed doses and ARIA-monitoring gaps emerge with home use

Possible Resolves by Aug 24, 2027

Discussed by: Clinicians and health economists quoted in Being Patient

At-home dosing shifts responsibility to patients and caregivers, raising the risk of missed or late doses. It also complicates the monitoring of ARIA — brain swelling and bleeding — since specialty pharmacies may hold refills until MRI scans are reviewed. Whether this becomes a real problem will show up in real-world safety data.

Eli Lilly counters with its own at-home anti-amyloid option

Possible Resolves by Aug 24, 2027

Discussed by: Analysts tracking the Alzheimer's treatment market

Lilly's rival antibody Kisunla remains an intravenous infusion. Eisai's move pressures Lilly to develop a subcutaneous version to avoid ceding the convenience advantage in the early-Alzheimer's market. A development or trial announcement is the expected response if the pressure is real.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2001–2010

Multiple sclerosis goes self-injected (2000s)

MS disease-modifying drugs, once given by infusion, moved to self-injected pens patients could use at home. This cut clinic visits dramatically and became the standard for a generation of patients.

Then

Adherence and patient independence improved across the MS population.

Now

It established the regulatory and usability framework for at-home biologic delivery in chronic neurologic disease.

Why this matters now

Alzheimer's care is now following the same path, with elderly patients and caregivers managing treatment at home.

2013–2019

Herceptin moves from IV to subcutaneous (2013–2019)

Roche turned its breast cancer blockbuster Herceptin into a five-minute subcutaneous injection, approved in Europe in 2013 and the US in 2019. The shift cut administration time from roughly 90 minutes to minutes and let some patients get treatment at home.

Then

Subcutaneous Herceptin captured a large share of the patient base in Europe within a few years.

Now

It proved a major biologic could move from IV to home injection without losing efficacy, setting the template for drug delivery innovation.

Why this matters now

IQLIK follows the same playbook for Alzheimer's — the identical drug molecule in a more convenient format.

2021–2024

Aduhelm's failed launch (2021–2024)

Biogen's first Alzheimer's antibody won accelerated approval in 2021 despite murky trial data and a controversial price. Medicare refused broad coverage, sales collapsed, and Biogen withdrew the drug, writing off billions.

Then

Aduhelm's failure chilled the anti-amyloid market and shaped Medicare reimbursement decisions.

Now

It raised the bar for proving benefit, pushing Leqembi toward a stricter trial design and more cautious rollout.

Why this matters now

Leqembi's slow adoption after 2023 shows efficacy alone does not drive uptake — delivery logistics do. IQLIK targets that lesson directly.